

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

Claims 1-13 (Canceled)

Claim 14 (Original)      A method of treating a skin condition or disease characterized by ulceration, inflammation, or blistering of the skin, comprising applying to the skin an allantoin-containing composition in a therapeutically effective amount, the allantoin-containing comprising an oil-in-water emulsion comprising:

- (a) allantoin;
- (b) an emollient component comprising:
  - (i) lanolin oil;
  - (ii) cetyl alcohol;
  - (iii) stearyl alcohol; and
  - (iv) cod liver oil; and
- (c) butylated hydroxytoluene;

(d) an emulsifier system comprising at least one nonionic emulsifier that is an ethoxylated ether or an ethoxylated ester whose carbon chain length ranges from 8 to 22 carbon atoms; and

(e) at least one acid selected from the group consisting of:

(i) an organic acid of from 2 to 22 carbon atoms; and

(ii) an inorganic acid selected from the group consisting of

hydrochloric acid, sulfuric acid, and phosphoric acid to adjust the pH from about 3.0 to about 6.0.

Claim 15 (Original)      The method of claim 14 wherein the pH of the composition is from about 4.5 to about 5.8.

Claim 16 (Original)      The method of claim 14 wherein the skin condition or disease is selected from the group consisting of epidermolysis bullosa, decubitus ulcers, pressure ulcers, diabetic ulcers, and milia.

Claim 17 (Original)      The method of claim 16 wherein the skin condition or disease is epidermolysis bullosa.

Claim 18 (Original)      The method of claim 14 further comprising administering

an additional therapeutic agent in a therapeutically effective quantity.

Claim 19 (Original)      The method of claim 18 wherein the additional therapeutic agent is selected from the group consisting of steroids, nonsteroidal anti-inflammatory agents, leukotriene antagonists, and monoclonal antibodies.

Claim 20 (Original)      A method of treating a skin condition or disease characterized by ulceration, inflammation, or blistering of the skin comprising applying to the skin an allantoin-containing composition in a therapeutically effective amount, the allantoin-containing composition comprising an oil-in-water emulsion comprising:

(a) allantoin;

(b) an emulsifier system including at least one nonionic emulsifier that is an ethoxylated ether or an ethoxylated ester whose carbon chain length ranges from 8 to 22 carbon atoms, the pH of the emulsion being from about 3.0 to about 6.0 after the addition of acid to bring the pH into the range of from about 3.0 to about 6.0.

Claim 21 (Original)      The method of claim 20 wherein the pH of the composition is from about 4.5 to about 5.8.

Claim 22 (Original)      The method of claim 20 wherein the skin condition or disease is selected from the group consisting of epidermolysis bullosa, decubitus ulcers, pressure ulcers, diabetic ulcers, and milia.

Claim 23 (Original)      The method of claim 22 wherein the skin condition or disease is epidermolysis bullosa.

Claim 24 (Original)      The method of claim 20 further comprising administering an additional therapeutic agent in a therapeutically effective quantity.

Claim 25 (Original)      The method of claim 24 wherein the additional therapeutic agent is selected from the group consisting of steroids, nonsteroidal anti-inflammatory agents, leukotriene antagonists, and monoclonal antibodies.

Claim 26 (Original)      The method of claim 20 wherein the composition further comprises at least one of:

(a) an emollient component comprising at least one ingredient selected from the group consisting of lanolin oil, cetyl alcohol, stearyl alcohol, and cod liver oil;

(b) butylated hydroxytoluene;

(c) at least one herbal extract selected from the group consisting of St. John's

wort extract, witch hazel extract, chamomile extract, and arnica extract;

(d) a preservative component comprising at least one preservative selected from the group consisting methylparaben, propylparaben, and diazolidinyl urea;

(e) tetrasodium EDTA; and

(f) a solvent component comprising at least one solvent selected from the group consisting of propylene glycol, butylene glycol, and glycerin.

Claims 26-133 (Canceled)